An Italian study published in Nature Medicine provides compelling evidence that fecal microbiota transplantation (FMT) can enhance the effectiveness of immunotherapy in patients with advanced metastatic renal cell carcinoma (mRCC). The research was coordinated by Università Cattolica del Sacro Cuore and Fondazione Policlinico Gemelli IRCCS and represents a significant step forward in understanding how the gut microbiota modulates cancer treatment outcomes.
This article was originally published on MedicalXpress.com
